

HemoShear announces appointment of Vice Presidents

HemoShear is enhancing its management team as the company readies to enter the clinic and expand its pipeline.

Michael Simmers, PhD, MBA, has been promoted to Vice President of Operations and is responsible for laboratory operations, the Company's intellectual property portfolio, technology advancement, facilities and general infrastructure. Dr. Simmers received his bachelor's degree and PhD in Biomedical Engineering from the University of Virginia (UVA), while playing an important role in development of the first generation of the Company's *REVEAL-Tx™* technology at UVA. He joined HemoShear in 2010 immediately after earning his PhD. In addition to proving himself to be a strong and trusted leader of people, Dr. Simmers carefully guided HemoShear through a highly successful 2020 without interruption by COVID-19. Dr. Simmers received his MBA last year from the University of Massachusetts



Susan Klees has been appointed Vice President of Communications and is responsible for communications with patient and scientific communities, marketing and public relations. Ms. Klees has worked with HemoShear as a consultant for the past two years. She has been a senior counselor to biotech and pharma clients for more than 20 years. Most recently, Ms. Klees served as Director of Communications for the Focused Ultrasound Foundation, raising global awareness of a disruptive, non-invasive technology to treat a number of severe diseases. Previously she led the Washington DC healthcare public relations practice for Ketchum, where she oversaw communications for Wyeth's women's health portfolio and GSK's oncology pipeline. A passionate advocate, she has created numerous patient education campaigns, including helping to launch Stand Up to Cancer. Ms. Klees received a B.A. in communications studies from the University of California, Los Angeles.



"Susan and Mike have earned recognition for their valuable contributions to the growth of HemoShear," said Brian Wamhoff, co-founder and Chief Operating Officer. "Susan has been instrumental in our external communications and engaging with patient advocacy groups as we advance HST5040 (an oral medication) into clinical studies to treat patients with methylmalonic or propionic acidemia, while Mike Simmers is preparing the Company's infrastructure to expand our drug discovery pipeline in rare diseases."